WO2022112806A3 - Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof - Google Patents
Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof Download PDFInfo
- Publication number
- WO2022112806A3 WO2022112806A3 PCT/HU2021/000014 HU2021000014W WO2022112806A3 WO 2022112806 A3 WO2022112806 A3 WO 2022112806A3 HU 2021000014 W HU2021000014 W HU 2021000014W WO 2022112806 A3 WO2022112806 A3 WO 2022112806A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- infection
- ibv
- coronaviruses
- cov
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 235000015872 dietary supplement Nutrition 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 241000711573 Coronaviridae Species 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 8
- 239000000370 acceptor Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000002894 organic compounds Chemical class 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- -1 methyl (hydroxy methyl ) groups Chemical group 0.000 abstract 1
- 230000011987 methylation Effects 0.000 abstract 1
- 238000007069 methylation reaction Methods 0.000 abstract 1
- 230000017693 oxidative demethylation Effects 0.000 abstract 1
- 238000007067 oxidative demethylation reaction Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is for use in the control of COVID- 19 coronavirus infection, which became worldwide in 2020. The present invention relates to the methylation of a metabolite, macromolecule, protein, RNA, DNA involved in a multicomponent food supplement with easily mobilizable methyl groups for the control of viral infection, preferably SARS-COV-2 and IBV coronaviruses, a pharmaceutical or pharmaceutical composition comprising at least one methyl donor and at least one methyl acceptor in such a way that that the ratio of methyl donors to methyl acceptors is in accordance with the preferred molar ratios. Definitions : Methyl donor compounds : Organic compounds methylated on N-, S- and 0 heteroatoms where methyl groups thereof transfer into transmethylation cycle after oxidative demethylation. Methyl acceptor compounds : Organic compounds for use in binding methyl (hydroxy methyl ) groups. The invention also relates to a formulation method and a method of administration for use in preparing the compositions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21890365.6A EP4210505A2 (en) | 2020-09-11 | 2021-11-10 | Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP-2000298 | 2020-09-11 | ||
HU2000298A HUP2000298A1 (en) | 2020-09-11 | 2020-09-11 | Food supplement or medicinal or pharmaceutical composition to control viral infection, particularly sars-cov-2 and ibv coronaviruses and their formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022112806A2 WO2022112806A2 (en) | 2022-06-02 |
WO2022112806A3 true WO2022112806A3 (en) | 2022-09-01 |
Family
ID=89993188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2021/000014 WO2022112806A2 (en) | 2020-09-11 | 2021-11-10 | Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4210505A2 (en) |
HU (1) | HUP2000298A1 (en) |
WO (1) | WO2022112806A2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1124548A2 (en) * | 1998-10-30 | 2001-08-22 | MERCK PATENT GmbH | Compositions for the treatment and prevention of cardiovascular diseases |
EP2283835A2 (en) * | 2002-06-19 | 2011-02-16 | N.V. Nutricia | Method and preparation for treating metabolic stress |
US20200054660A1 (en) * | 2016-12-09 | 2020-02-20 | St. Jude Children's Research Hospital | Dna methylation profiling for t-cell immunotherapy |
WO2021202245A1 (en) * | 2020-04-02 | 2021-10-07 | Egaceutical Corporation | Viral treatment regimens |
-
2020
- 2020-09-11 HU HU2000298A patent/HUP2000298A1/en unknown
-
2021
- 2021-11-10 EP EP21890365.6A patent/EP4210505A2/en not_active Withdrawn
- 2021-11-10 WO PCT/HU2021/000014 patent/WO2022112806A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1124548A2 (en) * | 1998-10-30 | 2001-08-22 | MERCK PATENT GmbH | Compositions for the treatment and prevention of cardiovascular diseases |
EP2283835A2 (en) * | 2002-06-19 | 2011-02-16 | N.V. Nutricia | Method and preparation for treating metabolic stress |
US20200054660A1 (en) * | 2016-12-09 | 2020-02-20 | St. Jude Children's Research Hospital | Dna methylation profiling for t-cell immunotherapy |
WO2021202245A1 (en) * | 2020-04-02 | 2021-10-07 | Egaceutical Corporation | Viral treatment regimens |
Non-Patent Citations (1)
Title |
---|
MCCADDON ANDREW ET AL: "COVID-19: A methyl-group assault?", MEDICAL HYPOTHESES, vol. 149, 1 April 2021 (2021-04-01), US, pages 110543, XP055942678, ISSN: 0306-9877, DOI: 10.1016/j.mehy.2021.110543 * |
Also Published As
Publication number | Publication date |
---|---|
HUP2000298A1 (en) | 2022-03-28 |
WO2022112806A2 (en) | 2022-06-02 |
EP4210505A2 (en) | 2023-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wiesner et al. | Fosmidomycin for the treatment of malaria | |
BR0213522B8 (en) | hydroxypyrimidinone derivative compounds, pharmaceutical composition, and use of a compound | |
NO20100302L (en) | Compositions containing organic compounds | |
MXPA03002022A (en) | Multivalent neuraminidase inhibitor conjugates. | |
WO2001022791A8 (en) | Controlled release compositions comprising nimesulide | |
FI3785730T3 (en) | Aluminium compounds for use in therapeutics and vaccines | |
BR9907832A (en) | Composition of sulfite-containing propofol | |
BRPI0408085A (en) | composition and method for the treatment and prevention of bacterial enteric infections | |
RS50972B (en) | Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate | |
AP1776A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor. | |
UA102187C2 (en) | Diindolylmethane-containing pharmaceutical composition for oral administration | |
WO2022112806A3 (en) | Food supplement or medicinal or pharmaceutical composition inhibiting virus infection, advantageously infection of sars-cov-2 and ibv coronaviruses and formulation thereof | |
PT1175489E (en) | OLIGONUCLEOTIDES CONTAINING AN ANTISENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
BR9912142A (en) | Substituted 6-benzyl-4-oxypyrimidines, process for their preparation and compositions containing them | |
BR9908458A (en) | 11beta-benzaldoxim-estra-4,9-dienocarbonic acid thiolesters replaced by s, processes for their preparation and pharmaceutical preparations containing these compounds | |
BRPI0507326A (en) | solid retarded formulation for parenteral administration | |
BRPI0614197B8 (en) | pharmaceutically effective composition in a dosage form for peroral administration containing at least one of the active ingredients indomethacin and acemetacin, forms of administration, and use of the composition | |
WO2007124700A3 (en) | Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof | |
BR112022019198A2 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF EPIDEMIC RIBONUCLEIC ACID VIRUS INFECTIONS, AND, USE OF A THERAPEUTICLY EFFECTIVE AMOUNT OF PIRONARIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ARTEMISININ OR A DERIVATIVE THEREOF | |
WO2013066208A3 (en) | Pharmaceutical composition based on epigallocatechin gallate-containing nano-micelles and use thereof | |
AU1039400A (en) | Opioid analgesic | |
HUP0004701A2 (en) | New salts of desloratadine, pharmaceutical compositions containing them and process for the preparation thereof | |
WO2022090807A3 (en) | Cannabigerol and tetrahydrocannabivarin antidote formulations and methods of using the same | |
EE05007B1 (en) | 9a-N- (N'-arylcarbamoyl) - and 9a-N- (N'-arylthiocarbamoyl) -9-deoxo-9a-aza-9a-homoerum thromycin Ahalogen derivatives, process for their preparation, pharmaceutical composition and use | |
EE200200599A (en) | Cyclostostin Compound for use as an antidiabetic drug, pharmaceutical preparation containing it, preparation of the compound and preparation and microorganism necessary for this |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 202337026542 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021890365 Country of ref document: EP Effective date: 20230411 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21890365 Country of ref document: EP Kind code of ref document: A2 |